Telix Pharmaceuticals Limited (TLX)

Market Cap	2.96B -49.6%
Revenue (ttm)	803.79M +55.6%
Net Income	-7.13M
EPS	-0.02
Shares Out	338.78M
PE Ratio	n/a
Forward PE	117.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	374,130
Open	8.78
Previous Close	8.57
Day's Range	8.69 - 8.96
52-Week Range	6.28 - 20.00
Beta	1.22
Analysts	Strong Buy
Price Target	21.13 (+141.49%)
Earnings Date	Apr 17, 2026

About TLX

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 1,184
• Stock Exchange: NASDAQ
• Ticker Symbol: TLX
• Website: https://telixpharma.com

Analyst Summary

According to 4 analysts, the average rating for TLX stock is "Strong Buy." The 12-month stock price target is $21.13, which is an increase of 141.49% from the latest price.

Price Target

$21.13

(141.49% upside)

Analyst Consensus: Strong Buy